SCHEMBL480447

SCHEMBL480447

CCOC(=O)c1ccc2c(c1)NC(=O)C2=C(Nc1ccc(C(C)(C)N)c(F)c1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.39
GAA P10253 3/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPK1 P28482 1/20 0.39
MAPT P10636 6/20 0.37
TP53 P04637 1/20 0.37
THRB P10828 1/20 0.37
BACE1 P56817 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
ALDH1A1 P00352 2/20 0.37
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
NAMPT P43490 1/20 0.37
USP2 O75604 1/20 0.36
POLB P06746 2/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2123987 0.92 RXFP1 (0.45) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL2121157 0.91 RXFP1 (0.44) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL480689 0.91 RXFP1 (0.45) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL480445 0.91 RXFP1 (0.45) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL19133988 0.90 RXFP1 (0.44) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL479819 0.90 RXFP1 (0.44) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL2121050 0.90 RXFP1 (0.44) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL479442 0.87 SMN1; SMN2 (0.42) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL2573629 0.87 RXFP1 (0.49) RXFP1SMN1; SMN2GAARAB9ANPC1
SCHEMBL19133990 0.86 RXFP1 (0.41) RXFP1SMN1; SMN2GAARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9844572-B2 Promotion of neuronal integration in neural stem cell grafts LIFE & BRAIN GMBH (DE) 2017-12-19 US disclosed
EP-2411034-B1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2017-07-26 EP disclosed
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2012-04-19 US disclosed
EP-2411034-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS Life & Brain GmbH (DE) 2012-02-01 EP disclosed
WO-2010108665-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS DCX, NGF, BDNF RXFP1 2731/4885SMN1; SMN2 60/4885GAA 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.